Dicerna Pharmaceuticals
Oct 31, 2016

Dicerna to Report Third Quarter 2016 Financial Results and Host Conference Call on November 7, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Company will release its third quarter 2016 financial results after market close on Monday, November 7, 2016.

Management will conduct a conference call at 4:30 p.m. ET that day to discuss the Company's financial results and provide a general business update. The conference call will be webcast live via the internet and will be available on the "Investors & Media" section of the Dicerna website, www.dicerna.com. The webcast will also be archived on the Company's website.

The call can also be accessed by dialing (855) 453-3834 or (484) 756-4306 (international), and referencing conference ID 10030267 prior to the start of the call. After the conference call, a replay will be available until November 14, 2016. To access the replay, please dial (855) 859-2056 or (404) 537-3406, and refer to conference ID 10030267.

About Dicerna Pharmaceuticals, Inc.

Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery and development of innovative RNA interference (RNAi)-based therapeutics for rare diseases involving the liver and for other diseases involving the liver such as chronic liver diseases, cardiovascular diseases, and viral infectious diseases. The Company is using its proprietary GalXC™ RNAi technology platform to build a broad pipeline in these core therapeutic areas. Dicerna is pursuing target genes where connections between target gene and diseases are well understood and documented. The Company intends to discover, develop and commercialize these novel therapeutics either on its own or in collaboration with pharmaceutical partners. For more information, please visit www.dicerna.com.

Investors:
Rx Communications Group
Melody Carey, 917-322-2571
mcarey@rxir.com
or
Media:
SmithSolve
Alex Van Rees, 973-442-1555 ext. 111
alex.vanrees@smithsolve.com

Source: Dicerna Pharmaceuticals, Inc.

News Provided by Acquire Media